Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents

Hypertension

Volumn 61, Issue 4, 2013, Pages 901-907

  Kavvadas, Panagiotis ^a   Weis, Lise ^a   Abed, Ahmed B ^a   Feldman, David L ^b   Dussaule, Jean Claude ^a   Chatziantoniou, Christos ^a  

^a HÔPITAL TENON   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aliskiren; fibrosis; renal disease regression; renin

Indexed keywords

ALISKIREN; ATRIAL NATRIURETIC FACTOR; BONE MORPHOGENETIC PROTEIN 4; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; DNA METHYLTRANSFERASE 1; HYDRALAZINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; OSTEOGENIC PROTEIN 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DNA METHYLATION; ENZYME ACTIVATION; GLOMERULUS FILTRATION RATE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REMISSION; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TRANSGENIC MOUSE; TREATMENT DURATION; UPREGULATION;

AMIDES; ANIMALS; DISEASE MODELS, ANIMAL; FIBROSIS; FUMARATES; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MICE; MICE, TRANSGENIC; RENIN;

EID: 84875222938     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00639     Document Type: Article

References (28)

1. Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604-615.
2. Rahuel J, Rasetti V, Maibaum J, Rüeger H, Göschke R, Cohen NC, Stutz S, Cumin F, Fuhrer W, Wood JM, Grütter MG. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7:493-504.
3. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int. 2009;76:23-31.
4. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:2930-2934.
5. Moriyama T, Tsuruta Y, Kojima C, Itabashi M, Sugiura H, Takei T, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Int Urol Nephrol. 2012;44:841-845.
6. Tain YL, Hsu CN, Lin CY, Huang LT, Lau YT. Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats. Eur J Pharmacol. 2011;670:561-565.
7. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro) renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008;52:130-136.
8. Caron KM, James LR, Kim HS, Morham SG, Sequeira Lopez ML, Gomez RA, Reudelhuber TL, Smithies O. A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci USA. 2002;99:8248-8252.
9. Lu H, Rateri DL, Feldman DL, Jr RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118:984-993.
10. Choi DE, Jeong JY, Lim BJ, Chang YK, Na KR, Shin YT, Lee KW. Aliskiren ameliorates renal inflammation and fibrosis induced by unilateral ureteral obstruction in mice. J Urol. 2011;186:694-701.
11. Huby AC, Rastaldi MP, Caron K, Smithies O, Dussaule JC, Chatziantoniou C. Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin. PLoS ONE. 2009;4:e6721.
12. Hannken T, Schroeder R, Zahner G, Stahl RA, Wolf G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol. 2000;11:1387-1397.
13. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 2010;16:535-43, 1p following 143.
14. Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu MJ. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol Renal Physiol. 2010;299:F929-F941.
15. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Müller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens. 2011;24:355-361.
16. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569-576.
17. Fischer R, Dechend R, Qadri F, et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension. Hypertension. 2008;51:540-546.
18. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-3306.
19. de Borst MH, Navis G, de Boer RA, Huitema S, Vis LM, van Gilst WH, van Goor H. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab Invest. 2003;83:1761-1770.
20. Iekushi K, Taniyama Y, Kusunoki H, Azuma J, Sanada F, Okayama K, Koibuchi N, Iwabayashi M, Rakugi H, Morishita R. Hepatocyte growth factor attenuates transforming growth factor-ß-angiotensin II crosstalk through inhibition of the PTEN/Akt pathway. Hypertension. 2011;58:190-196.
21. Chiang CK, Hsu SP, Wu CT, Huang JW, Cheng HT, Chang YW, Hung KY, Wu KD, Liu SH. Endoplasmic reticulum stress implicated in the development of renal fibrosis. Mol Med. 2011;17:1295-1305.
22. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17-25.
23. Bechtel W, McGoohan S, Zeisberg EM, Müller GA, Kalbacher H, Salant DJ, Müller CA, Kalluri R, Zeisberg M. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 2010;16:544-550.
24. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol. 2003;14:1132-1144.
25. Helle F, Iversen BM, Chatziantoniou C. Losartan increases NO release in afferent arterioles during regression of L-NAME-induced renal damage. Am J Physiol Renal Physiol. 2010;298:F1170-F1177.
26. Mori T, Cowley AW Jr. Role of pressure in angiotensin II-induced renal injury: chronic servo-control of renal perfusion pressure in rats. Hypertension. 2004;43:752-759.
27. Mori T, Polichnowski A, Glocka P, Kaldunski M, Ohsaki Y, Liang M, Cowley AW Jr. High perfusion pressure accelerates renal injury in saltsensitive hypertension. J Am Soc Nephrol. 2008;19:1472-1482.
28. Polichnowski AJ, Lu L, Cowley AW Jr. Renal injury in angiotensin II+LNAME- induced hypertensive rats is independent of elevated blood pressure. Am J Physiol Renal Physiol. 2011;300:F1008-F1016.